Physician profile
Yvette Murillo
NPI 1225363989
$1,204.71
in general payments reported to CMS, 2019-2025
18 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.00 · 2022: $25.27 · 2023: $151 · 2024: $508 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $236.63 | 2025 | Enhertu |
| Astellas Pharma US INC | $136.25 | 2021-2024 | Padcev |
| Novo Nordisk INC | $124.81 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $121.85 | 2024 | Libtayo |
| Merck Sharp & Dohme LLC | $120.55 | 2023-2025 | Keytruda |
| Abbvie INC. | $95.64 | 2024 | |
| Taiho Oncology, INC. | $76.02 | 2024 | |
| Novartis Pharmaceuticals Corporation | $67.25 | 2023-2025 | |
| Emmaus Medical, INC. | $60.91 | 2023 | Endari |
| Celgene Corporation | $25.27 | 2022 | |
| Csl Behring | $24.85 | 2023 | Hemgenix |
| Takeda Pharmaceuticals U.S.A., INC. | $20.28 | 2025 | Iclusig |
| Lilly USA, LLC | $19.36 | 2025 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $16.50 | 2023 | Lynparza |
| Kedrion Biopharma, INC. | $15.96 | 2025 | Kedrab, Koate, Gammaked |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $14.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.38 | 2023 | Xarelto |
| Emd Serono, INC. | $13.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.